– Dr. Balaguer, scientific director of the UDIC, has directed the course of Coordination and Practical Management of clinical trials in Neurology (module from 5:30 hours). Completed during the LXX Annual Meeting of the Spanish Society of Neurology (Seville, 24 November 2018).
– Continue the development of our projects in Parkinson’s disease: anti-alfasinuclein monoclonal antibodies, gastric-retention levodopa, antidiscinetic drug in advanced Parkinson’s, new drug against hallucinations and delusions in Parkinson’s disease dementia.
– UDIC is performing several clinical trials in Alzheimer’s disease: oral drug acting like inhibitor of amyloid, anti-amyloid monoclonal antibodies (intravenously and subcutaneously), neuromodulator drug in moderated Alzheimer’s disease.
– Many patients still are taking part in a study in Progressive Supranuclear Paralysis with an anti-tau monoclonal antibodies.